Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Vitale, Cristiana ^a   Rosano, Giuseppe M C ^a,b   Prasad, Krishna ^c  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular; Clinical trials; Cost effectiveness; Diabetes mellitus; Dipeptidyl peptidase 4 inhibitors; Empagliflozin; Healthcare; Regulatory

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; EMPAGLIFLOZIN; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ANTIDIABETIC ACTIVITY; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; GLYCEMIC CONTROL; HUMAN; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK REDUCTION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ECONOMICS; GLUCOSE BLOOD LEVEL;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85007415224     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0379-4     Document Type: Note

References (10)

1. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.
2. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35.
3. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-42.
4. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015. doi:10.1016/S0140-6736(14)62225-X.
5. McMurray J. The Vildagliptin in ventricular dysfunction diabetes (VIVIDD) trial. Presented at the Heart Failure Congress. 2013; (Lisbon, Portugal, May 25-28, 2013:99).
6. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579-88.
7. Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes. 2015;6:1092-6.
8. Nathan DM. Finding new treatments for diabetes-how many, how fast. how good? N Engl J Med. 2007;356:437-40.
9. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-28.
10. Rapporto sull'Uso dei Farmaci in Italia relativo all'anno 2014-OSMEDhttp://www.agenziafarmaco.gov.